Home Tools
Log in
Cart

c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.
Cat No. product name
T2516 Amuvatinib Amuvatinib is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
T2208 Bacitracin Zinc Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from M...
T1661 Crizotinib Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
T6154 SU11274 SU11274(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
T5S1331 Herbacetin 1. Herbacetin induces apoptosis in HepG2 cells, by ROS and PI3K/Akt pathway. 2. Herbacetin suppresses the HGF-induced motility of human breast cancer MDA-MB-231 ...
T5164 Cabozantinib hydrochloride Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
T6351 MGCD-265 analog MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with ...
T9601 Tepotinib hydrochloride(1 : x) Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 s...
T5656 (±)-Norcantharidin Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
T17184 Tyrosine kinase inhibitor Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
T22324 Ensartinib hydrochloride Ensartinib dihydrochloride is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK...
T2185 L-Ascorbic acid 2-phosphate trisodium L-Ascorbic acid 2-phosphate (AA2P) is used in biocatalytic dephosphorylation for electric power generation and electrochemical detection assays.
T6057 URMC-099 URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
T6907 NPS-1034 NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
T8399 Crizotinib hydrochloride Crizotinib hydrochloride is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)
T1797 Cabozantinib S-malate Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential a...
T6128 PHA-665752 PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
T2586 Cabozantinib Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).
T5349 SCR-1481B1 SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor
T3455 Merestinib LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. LY2801653 selectively b...
T2054 Altiratinib Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth ...
T2282 RPI-1 RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
T1963 Capmatinib Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
T6260 AMG-208 AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
T1918 NVP-TAE 226 NVP-TAE226 is an effective FAK inhibitor (IC50: 5.5 nM) and most effective to Pyk2(IC50: 3.5 nM); 10- to 100-fold less effective against IGF-1R, InsR, c-Met, and...
T6117 Tivantinib Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
T5467 SAR125844 SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)
T2293 SGX-523 SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
T25492 Hepln-13 Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
T2419 BMS-794833 BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
T2349 BMS-754807 Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine ...
T2894 Norcantharidin Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
T2699 BMS 777607 BMS-777607 is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of Malignant Sol...
T2676 PF-04217903 MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.
T2680 NVP-BVU972 NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
T7900 BAY-474 BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe
T7787 BMS817378 BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).
T9052 XL092 JUN04542 is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
T8825 Capmatinib 2HCl.H2O Capmatinib 2HCl.H2O is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
T8326 BMS-2 BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
T8416 Capmatinib xHCl Capmatinib xHCl is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = 0.13 nM) as...
T8409 SYN1143 AMG-1 is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and...
T12418 PF-04217903 phenolsulfonate PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
T12417 PF-04217903 methanesulfonate PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
T13108 Pamufetinib TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectivel...
T13194 CSF1R-IN-2 CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
T10585 Bozitinib Bozitinib (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding p...
T10655 C-Met inhibitor 1 c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
T10654 C-Met-IN-2 c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.
T10653 C-met-IN-1 c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.
Amuvatinib
T2516
Amuvatinib is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
Bacitracin Zinc
T2208
Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from M...
Crizotinib
T1661
Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
SU11274
T6154
SU11274(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
Herbacetin
T5S1331
1. Herbacetin induces apoptosis in HepG2 cells, by ROS and PI3K/Akt pathway. 2. Herbacetin suppresses the HGF-induced motility of human breast cancer MDA-MB-231 ...
Cabozantinib hydrochloride
T5164
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
MGCD-265 analog
T6351
MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with ...
Tepotinib hydrochloride(1 : x)
T9601
Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 s...
(±)-Norcantharidin
T5656
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
Tyrosine kinase inhibitor
T17184
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
Ensartinib hydrochloride
T22324
Ensartinib dihydrochloride is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK...
L-Ascorbic acid 2-phosphate trisodium
T2185
L-Ascorbic acid 2-phosphate (AA2P) is used in biocatalytic dephosphorylation for electric power generation and electrochemical detection assays.
URMC-099
T6057
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
NPS-1034
T6907
NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
Crizotinib hydrochloride
T8399
Crizotinib hydrochloride is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)
Cabozantinib S-malate
T1797
Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential a...
PHA-665752
T6128
PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
Cabozantinib
T2586
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).
SCR-1481B1
T5349
SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor
Merestinib
T3455
LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. LY2801653 selectively b...
Altiratinib
T2054
Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth ...
RPI-1
T2282
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
Capmatinib
T1963
Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
AMG-208
T6260
AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
NVP-TAE 226
T1918
NVP-TAE226 is an effective FAK inhibitor (IC50: 5.5 nM) and most effective to Pyk2(IC50: 3.5 nM); 10- to 100-fold less effective against IGF-1R, InsR, c-Met, and...
Tivantinib
T6117
Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
SAR125844
T5467
SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)
SGX-523
T2293
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
Hepln-13
T25492
Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
BMS-794833
T2419
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
BMS-754807
T2349
Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine ...
Norcantharidin
T2894
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
BMS 777607
T2699
BMS-777607 is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of Malignant Sol...
PF-04217903
T2676
MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.
NVP-BVU972
T2680
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
BAY-474
T7900
BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe
BMS817378
T7787
BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).
XL092
T9052
JUN04542 is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
Capmatinib 2HCl.H2O
T8825
Capmatinib 2HCl.H2O is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
BMS-2
T8326
BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
Capmatinib xHCl
T8416
Capmatinib xHCl is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = 0.13 nM) as...
SYN1143
T8409
AMG-1 is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and...
PF-04217903 phenolsulfonate
T12418
PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
PF-04217903 methanesulfonate
T12417
PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
Pamufetinib
T13108
TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectivel...
CSF1R-IN-2
T13194
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
Bozitinib
T10585
Bozitinib (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding p...
c-Met inhibitor 1
T10655
c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
c-Met-IN-2
T10654
c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.
c-met-IN-1
T10653
c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.
1 2